Hyperion Therapeutics, Inc. (HPTX)
-NasdaqGM 22.33 0.00(0.00%) May 17, 4:00PM EDT|After Hours
:
22.00 
0.33 (1.48%) May 17, 4:45PM EDT
| Prev Close: | 22.33 |
|---|
| Open: | 22.45 |
|---|
| Bid: | 21.50 x 100 |
|---|
| Ask: | 22.00 x 100 |
|---|
| 1y Target Est: | 29.33 |
|---|
| Beta: | 5.740 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 22.21 - 23.01 |
|---|
| 52wk Range: | 9.95 - 26.50 |
|---|
| Volume: | 589,241 |
|---|
| Avg Vol (3m): | 118,381 |
|---|
| Market Cap: | 447.54M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.56 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- HYPERION THERAPEUTICS INC FinancialsEDGAR Online Financials(Fri, May 17)
- HYPERION THERAPEUTICS INC Files SEC form 8-K, Other EventsEDGAR Online(Fri, May 17)
- Hyperion Therapeutics Added to NASDAQ Biotechnology Index (NBI)GlobeNewswire(Thu, May 16)
- HYPERION THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Thu, May 16)
- HYPERION THERAPEUTICS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- Hyperion Therapeutics Announces First Quarter 2013 Operating ResultsGlobeNewswire(Thu, May 9)
- HYPERION THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements andEDGAR Online(Thu, May 9)
- Hyperion Therapeutics to Report First Quarter 2013 Financial Results After Market on May 9, 2013GlobeNewswire(Mon, May 6)
- 3 Healthcare Stock Stories for Thursday Perusalat Wall St. Cheat Sheet(Thu, May 2)
- Why Hyperion Therapeutics Shares Shot Higherat Motley Fool(Thu, May 2)
- Hyperion Therapeutics drug gets FDA orphan statusAP(Thu, May 2)
- Hyperion Therapeutics receives orphan drug exclusivity from FDAtheflyonthewall.com(Thu, May 2)
- Hyperion Therapeutics Receives Orphan Drug Exclusivity From FDAGlobeNewswire(Thu, May 2)
- Hyperion Therapeutics Exercises Option to Acquire Rights to BUPHENYL(R) and AMMONUL(R)GlobeNewswire(Thu, May 2)
- Hyperion Therapeutics Becomes Oversold (HPTX)at TheStreet(Wed, May 1)
Key Statistics
| Forward P/E (1 yr): | 22.56 |
|---|
| P/S (ttm): | 571.57 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.60 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.11 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Hyperion Therapeutics, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology.
View More